KoreaTech Today - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTech Today - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Coronavirus

Samsung Biologics Inks Deal to Mass-Produce COVID-19 Treatment

 1,543 total views,  1 views today

James Jung by James Jung
PUBLISHED: April 9, 2020 UPDATED: April 18, 2020
in Coronavirus, Samsung Biologics, South Korea, Virus
0
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.

Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.

Samsung Biologics announced on Thursday that it signed with Vir Biotechnology Inc. a manufacturing agreement worth approximately $362 million (438 billion won) to mass-produce COVID-19 treatment.

Under the deal, the Korean biopharmaceutical company would commence large scale manufacturing for Vir’s SARS-CoV-2 (COVID-19) monoclonal antibody (mAb) treatment. Samsung Biologics said it would start with technology transfer as early as October this year. The company would begin manufacturing potential commercial batches by 2021 at its Songdo plant in Incheon.

Vir Biotechnology, Inc. is a clinical-stage immunology firm based in San Francisco specializing in creating treatment drugs for infectious disease prevention. The bioscience company developed antibodies from blood samples from those completely cured of the SARS (Severe Acute Respiratory Syndrome) illness. Vir’s antibody candidate is said to be highly potent in neutralizing the SARS-CoV-2 in live-virus cellular assays.

The U.S. company aims to proceed directly into phase 2 of clinical trials within the next three to five months. The biological contract manufacturing organization (CMO) build’s on its letter of intent with Biogen, Inc. and previously announced CMO with WuXi Biologics.

The U.S. Food and Drug Administration (FDA) is currently reviewing to certify a fast-tracking the designation of the antibody as a possible therapy to cure coronavirus infected patients.

Antibody Therapeutics Global Potential

Dr. Tae Han Kim, CEO of Samsung Biologics, said that with Vir’s antibody candidate coupled with Samsung Biologics’ production scale has the potential to give hope to millions of people suffering from the effects of COVID-19.

George Scangos, CEO of Vir Biotechnology, expects that the world would significantly need antibody therapies given the trajectory of the COVID-19 pandemic. He added that Samsung Biologics share their commitment to work with exceptional speed in addressing the pandemic.

With the latest CMO, Vir hopes to secure a stable manufacturing site for its mass production of therapeutics antibody. Samsung Biologics expects the manufacturing agreement would raise its brand awareness in the international manufacturing market.

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: antibodycoronavirusCOVID-19Samsung BiologicsSARS-CoV-2South Korea newstherapeuticstreatmentVir Biotechnology

Related Posts

South Korea curbs tech leaks to foreign countries
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

South Korea curbs tech leaks to foreign countries

February 8, 2022
Hyundai Rotem set to provide upgraded army tank variants to South Korea
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

Hyundai Rotem set to provide upgraded army tank variants to South Korea

February 2, 2022
S.Korea will track COVID-19 cases with AI-powered facial recognition from January
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

S.Korea will track COVID-19 cases with AI-powered facial recognition from January

December 14, 2021
South Korea sets site engineering standards for big tech firms
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
Google

South Korea sets site engineering standards for big tech firms

December 9, 2021
National AI complex project starts in South Korea: New AI hub in making
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
South Korea

National AI complex project starts in South Korea: New AI hub in making

November 25, 2021
Korea to expand bilateral ties with the U.S. to resolve semiconductor shortage
Samsung Biologics signed with Vir Biotechnology a manufacturing agreement worth approximately $362 million to mass-produce COVID-19 treatment.
Semiconductor

Korea to expand bilateral ties with the U.S. to resolve semiconductor shortage

November 20, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Best Korean Dramas To Watch This 2021

    0 shares
    Share 0 Tweet 0
  • Coway Changes Name After Netmarble’s Aquisition

    0 shares
    Share 0 Tweet 0
  • Top 8 South Korean Mobile MMORPG to Watch Out For in 2021

    0 shares
    Share 0 Tweet 0
  • SKT Popularizes Social VR with Ifland Metaverse Platform

    0 shares
    Share 0 Tweet 0
  • LG, Samsung to Reveal Advanced AI-Based Fridges at CES 2020

    0 shares
    Share 0 Tweet 0
  • Naver Cloud & Samsung Electronics to build the world’s first 5G driven cloud-based autonomous driving robot 

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |